A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population (IPACE-CVD)

Janssen (J&J Innovative Medicine)

Status: Completed

Conditions: Peripheral Artery Disease (PAD); Coronary Artery Disease (CAD)

Treatments: Device: Care4Today® Connect CAD-PAD Mobile Application

Study type: Observational

Funder types: Industry; Other

Identifiers

NCT06052319

NOPRODPEA0001 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to assess the engagement and usefulness of Care4Today® Connect CAD-PAD digital platform in participants with coronary artery disease or peripheral artery disease (CAD or PAD).

Enrollment: 277 patients

Sex: All

Ages: 40 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Must have a diagnosis of CAD and or PAD, who are on therapy or about to initiate therapy
• Own an iPhone or Android mobile device
• Have an active email account
• Must sign a participation agreement or informed consent form (ICF) allowing data collection in accordance with local requirements
• Willing to download and use Care4Today (C4T) CAD-PAD application (app)

Exclusion criteria

• Any cardiovascular conditions (for example, recent stroke, high bleeding risk, severe heart failure) or non-cardiovascular condition deemed as poor prognosis by the investigator and which may percent a patient from completing the study
• Unable to read or write the language used for the C4T (English, or Spanish if Spanish version is available)
• Visual or hearing impairment or mental disability that would preclude independent app use
• Patients currently using the C4T app prior to the signing of ICF

Trial design

277 participants in 1 patient group

Participants with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) or Both

Description:

Participants with CAD or PAD or both will be directed to download the Care4Today® (C4T) Connect CAD-PAD mobile application on iPhone or Android device to assess engagement and usefulness of C4T in disease management for 3 months. No study drug and other treatment(s) will be provided as a part of this study. All aspects of treatment and clinical management of participants will continue to be in accordance with local clinical practice and applicable local regulations, and at the discretion of the participating physician.

Treatment:

Device: Care4Today® Connect CAD-PAD Mobile Application